Phase

PHASE2 clinical trials

Active studies categorized as PHASE2 in the public registry.

294active studies

160recruiting now

46countries represented

147largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 2

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)Condition

MWN109 1, MWN109 2Treatment

China1 locations

Shanghai Minwei Biotechnology Co., LtdSponsor

Updated 2026-09-03 · NCT07801820See eligibility →

Recruiting nowPhase 2

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Overweight, Overweight and ObesityCondition

Counseling, Text MessagesTreatment

United States1 locations

Memorial Sloan Kettering Cancer CenterSponsor

Updated 2026-09-02 · NCT05770570See eligibility →

Recruiting nowPhase 2

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

Adults With Overweight/Obesity and Type 2 DiabetesCondition

AT673 low dose, AT673 high doseTreatment

United States8 locations

Antag TherapeuticsSponsor

Updated 2026-09-01 · NCT07724340See eligibility →

Recruiting nowPhase 2

Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)

Healthy Volunteers, OverweightCondition

Sucralose, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-09-01 · NCT03407079See eligibility →

Recruiting nowPhase 1, Phase 2

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

Obesity, Metabolic SyndromeCondition

Empagliflozin 25 MG, PlaceboTreatment

United States1 locations

Vanderbilt University Medical CenterSponsor

Updated 2026-09-01 · NCT05972564See eligibility →

Recruiting nowPhase 2

GLP-1R Agonist Treatment for Opioid Use Disorder

Opioid Use Disorder, Opioid Abuse and AddictionCondition

Semaglutide Pen Injector, PlaceboTreatment

United States4 locations

Milton S. Hershey Medical CenterSponsor

Updated 2026-08-28 · NCT06548490See eligibility →

Recruiting nowPhase 1, Phase 2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Overweight and/or Obesity, Weight ManagementCondition

ecnoglutide tablets, placebo with matching dosageTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07243171See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 2

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

Type 1 Diabetes, ObesityCondition

MetforminTreatment

United States1 locations

Heba M. IsmailSponsor

Updated 2026-08-21 · NCT05414409See eligibility →

Recruiting nowPhase 2

Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation

Obesity & Overweight, Bariatric EndoscopyCondition

Gastric fundal mucosal ablation (GFMA), Bariatric endoscopic antral myotomy (BEAM)Treatment

Egypt1 locations

Cairo UniversitySponsor

Updated 2026-08-21 · NCT07612527See eligibility →

Recruiting nowPhase 2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Overweight or ObesityCondition

Olatorepatide, PlaceboTreatment

United States5 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-20 · NCT07685808See eligibility →

Recruiting nowPhase 1, Phase 2

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

Diabete Type 2Condition

SG Depot 2 mg, SG Depot 4 mgTreatment

Israel1 locations

Mapi Pharma Ltd.Sponsor

Updated 2026-08-20 · NCT07563699See eligibility →

Recruiting nowPhase 2

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

B-cell Acute Lymphoblastic Leukemia, ObesityCondition

IDEAL2 InterventionTreatment

United States16 locations

Etan OrgelSponsor

Updated 2026-08-19 · NCT05082519See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

ObesityCondition

ARO-INHBE, PlaceboTreatment

Australia, New Zealand7 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-08-18 · NCT06700538See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 1, Phase 2

HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)

Pulmonary Hypertension, Heart Failure With Preserved Ejection FractionCondition

HS235, PlaceboTreatment

United States1 locations

35Pharma IncSponsor

Updated 2026-08-17 · NCT07123779See eligibility →

Recruiting nowPhase 2

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Prostate Carcinoma, Recurrent Prostate CarcinomaCondition

Antiandrogen Therapy, Behavioral InterventionTreatment

United States1 locations

City of Hope Medical CenterSponsor

Updated 2026-08-17 · NCT07202247See eligibility →

Recruiting nowPhase 2

Tirzepatide in MetALD

Metabolic Alcohol-associated Liver Disease, Alcohol Use DisorderCondition

Tirzepatide, PlaceboTreatment

United States1 locations

National Institute on Alcohol Abuse and Alcoholism (NIAAA)Sponsor

Updated 2026-08-12 · NCT07046819See eligibility →

Recruiting nowPhase 1, Phase 2

A Study to Evaluate ALN-2232 in Participants With Obesity

ObesityCondition

ALN-2232, PlaceboTreatment

Canada1 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-12 · NCT07463846See eligibility →

Recruiting nowPhase 2

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Opioid Use Disorder, Opioid Use Disorder, ModerateCondition

Tirzepatide, PlaceboTreatment

United States9 locations

T. John Winhusen, PhDSponsor

Updated 2026-08-11 · NCT06651177See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowPhase 2

Phentermine's Impact on Treatment in Teens

Childhood ObesityCondition

Phentermine, PlaceboTreatment

United States6 locations

Russell McCulloh, MDSponsor

Updated 2026-08-10 · NCT07282340See eligibility →

Recruiting nowPhase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Condition

ALN-PNP, TirzepatideTreatment

United States6 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-10 · NCT07527910See eligibility →

Recruiting nowPhase 2

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver DiseaseCondition

SemaglutideTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-08-10 · NCT03884075See eligibility →

Recruiting nowPhase 2

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Type 1 Diabetes MellitusCondition

Tirzepatide 2.5mg weekly, Placebo injection (normal saline)Treatment

Australia1 locations

Victor Chang Cardiac Research InstituteSponsor

Updated 2026-08-10 · NCT06820281See eligibility →

Recruiting nowPhase 2

Atomoxetine in Melanocortin Obesity Syndrome

Melanocortin Obesity Syndrome, MCOSCondition

Atomoxetine, PlaceboTreatment

United States3 locations

Icahn School of Medicine at Mount SinaiSponsor

Updated 2026-08-07 · NCT06899178See eligibility →

Recruiting nowPhase 2

Cannabis for Obesity Trial

ObesityCondition

Cannabis, PlaceboTreatment

United States1 locations

Joshua A. Lile, Ph.D.Sponsor

Updated 2026-08-07 · NCT06137365See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast Atypical Hyperplasia, Breast CarcinomaCondition

Biospecimen Collection, MammographyTreatment

United States3 locations

National Cancer Institute (NCI)Sponsor

Updated 2026-08-04 · NCT06195306See eligibility →

Recruiting nowPhase 2

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

Diabetes type1, ObesityCondition

Semaglutide Pen Injector, PlaceboTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-08-04 · NCT06411210See eligibility →

Recruiting nowPhase 2

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; StatusCondition

Tirzepatide, Standard medical treatmentTreatment

United States1 locations

Alaa SadaSponsor

Updated 2026-07-30 · NCT07573163See eligibility →

Recruiting nowPhase 1, Phase 2

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

Obesity, Type 2 DiabetesCondition

GUB-UCN2, PlaceboTreatment

Germany1 locations

Gubra A/SSponsor

Updated 2026-07-29 · NCT07702890See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowPhase 2

Sit Less, Interact and Move More (SLIMM) 2 Study

Chronic Kidney Diseases, ObesityCondition

SLIMM, Standard Resistance TrainingTreatment

United States2 locations

Srinvasan BeddhuSponsor

Updated 2026-07-27 · NCT05173714See eligibility →

Recruiting nowPhase 2

COMMETS- Combination MCI Metabolic Syndrome

Alzheimer Disease, Mild Cognitive ImpairmentCondition

Semaglutide, Intranasal insulinTreatment

Israel1 locations

Rutgers, The State University of New JerseySponsor

Updated 2026-07-27 · NCT06072963See eligibility →

Recruiting nowPhase 2, Phase 3

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Menopause, Menopause Hot FlashesCondition

Metformin, semaglutideTreatment

United States3 locations

University of Colorado, DenverSponsor

Updated 2026-07-21 · NCT06975111See eligibility →

Recruiting nowPhase 2

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

Infertility, Female, ObesityCondition

Estradiol PatchesTreatment

United States2 locations

University of Colorado, DenverSponsor

Updated 2026-07-21 · NCT06686537See eligibility →

Recruiting nowPhase 2

Multi-Site Trial of Tirzepatide for Smoking Cessation

Smoking Cessation, Smoking BehaviorsCondition

Tirzepatide, PlaceboTreatment

United States4 locations

University of Southern CaliforniaSponsor

Updated 2026-07-17 · NCT07602699See eligibility →

Recruiting nowPhase 2

Effect of Ketone Esters on Liver Fat Content and Metabolic Function

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, ObesityCondition

bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester), PlaceboTreatment

United States1 locations

Washington University School of MedicineSponsor

Updated 2026-07-15 · NCT07097506See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowPhase 2

FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

Hypertension, Hypertension (HTN)Condition

FIM intervention arm, FIM Usual Care ArmTreatment

United States4 locations

University of Illinois at ChicagoSponsor

Updated 2026-07-10 · NCT07332741See eligibility →

Recruiting nowPhase 2

Study of Tirzepatide for Recovery and Alcohol Use Management

Alcohol Use Disorder (AUD)Condition

Tirzepatide, Saline PlaceboTreatment

United States2 locations

Brigham and Women's HospitalSponsor

Updated 2026-07-09 · NCT06727331See eligibility →

Recruiting nowPhase 1, Phase 2

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Obesity, Diabetes Mellitus, Type 2Condition

ARO-ALK7, PlaceboTreatment

Australia, New Zealand8 locations

Arrowhead PharmaceuticalsSponsor

Updated 2026-07-08 · NCT06937203See eligibility →

Recruiting nowPhase 2

Oxytocin for Weight Loss in Adolescents

Obesity, Adolescent, OxytocinCondition

Oxytocin nasal spray, PlaceboTreatment

United States1 locations

Massachusetts General HospitalSponsor

Updated 2026-06-26 · NCT04551482See eligibility →

Recruiting nowPhase 2

Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

Overweight, ObesityCondition

KDS2010, KDS2010Treatment

South Korea3 locations

NeuroBiogen Co., LtdSponsor

Updated 2026-06-24 · NCT07009171See eligibility →

Recruiting nowPhase 2, Phase 3

Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure

Heart Failure With Reduced Ejection Fraction, ObesityCondition

Semaglutide Injectable Product, Calorie-restricted dietTreatment

Denmark1 locations

Jens D Hove, MD,PHDSponsor

Updated 2026-06-23 · NCT06423599See eligibility →

Recruiting nowPhase 2

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Obesity & OverweightCondition

ERX1000, PlaceboTreatment

United States3 locations

ERX PharmaceuticalsSponsor

Updated 2026-06-22 · NCT07570758See eligibility →

Recruiting nowPhase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver FatCondition

Maridebart cafraglutide, PlaceboTreatment

United States23 locations

AmgenSponsor

Updated 2026-06-18 · NCT07441252See eligibility →

Recruiting nowPhase 2

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Obesity and Cardiovascular RiskCondition

Oral BGE-102, Oral Placebo Matching BGE-102Treatment

Puerto Rico, United States13 locations

BioAge Labs, Inc.Sponsor

Updated 2026-06-18 · NCT07656727See eligibility →

Recruiting nowPhase 1, Phase 2

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

Alzheimer Dementia (AD)Condition

IL-2 (Aldesleukin), Semaglutide Plus IL-2Treatment

United States1 locations

The Methodist Hospital Research InstituteSponsor

Updated 2026-06-16 · NCT07651319See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Recruiting nowPhase 2

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Endometrioid Endometrial AdenocarcinomaCondition

Glucagon-like peptide 1 receptor agonistTreatment

United States1 locations

University of FloridaSponsor

Updated 2026-06-08 · NCT07107334See eligibility →

Recruiting nowPhase 2

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Crohn Disease (CD)Condition

Tirzepatide, Standard of care treatmentTreatment

United States3 locations

Washington University School of MedicineSponsor

Updated 2026-06-05 · NCT06976853See eligibility →

Recruiting nowPhase 2

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

Cerebral Small Vessel DiseaseCondition

GLP-1 receptor agonistTreatment

China, Hong Kong2 locations

Chinese University of Hong KongSponsor

Updated 2026-06-05 · NCT05356104See eligibility →

Recruiting nowPhase 2, Phase 3

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Atypical Endometrial Hyperplasia, Fertility IssuesCondition

Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral TabletTreatment

China1 locations

Xiaojun ChenSponsor

Updated 2026-06-04 · NCT05316493See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

PHASE2 clinical trials

Current studies

Related phases